Lessons from COVID-19 to increase opioid vaccine acceptance

Trends Pharmacol Sci. 2022 Dec;43(12):998-1000. doi: 10.1016/j.tips.2022.08.010. Epub 2022 Sep 7.

Abstract

COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.

Trial registration: ClinicalTrials.gov NCT04458545.

Keywords: COVID-19 vaccination; opioid misuse; opioid vaccination; public health; vaccine reluctance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Pandemics / prevention & control
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Analgesics, Opioid
  • Vaccines

Associated data

  • ClinicalTrials.gov/NCT04458545